Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Abbott Vascular Inc Product Pipeline Analysis Reference Code GDME6037PD

VIEWS: 62 PAGES: 75

Abbott Vascular Inc. - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the Abbott Vascular Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date. Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope - Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments. - Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase. - Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date. - Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application. - Data on relevant clinical trials and product patent details, wherever applicable. - Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility. Reasons

More Info
  • pg 1
									                                       Abbott Vascular Inc. - Product Pipeline Analysis
     Reference Code: GDME6037PD                                                                                            Publication Date: NOV 2010



     Company Snapshot                                                     Company Overview
     Key Information
                                                                          Abbott Vascular Inc. (Abbott Vascular) is engaged in the development,
      Abbott Vascular Inc., Key Facts                                     manufacture and marketing of a complete portfolio of vessel closure,
                                                                          endovascular and coronary products, which are used for treating patients
      Web Address                       www.abbottvascular.com
                                                                          with vascular disease. It is a division of Abbott Laboratories. The
      Turnover         (in      USD 353.70                                company developed a technology that transforms the treatment of
      Million)                                                            vascular disease and improves patient care by combining the latest
                                                                          medical device innovations. Its product portfolio includes the carotid stent
      Number of Employees               4,200                             systems, cobalt chromium coronary stent platforms, rapid exchange
      Industry                          Pharmaceuticals and Healthcare-   technology, balloon dilatation catheters, guide wires, and vessel closure
      Source:Primary / Secondary Research                                 technologies. Abbott Vascular is headquartered in California, the US.
      GlobalData




     Abbott Vascular Inc. Pipeline Products

      Abbott Vascular Inc. Key Pipeline Products by Equipment             Abbott Vascular Inc. Key Pipeline Products by Therapy Area
      Type
     Equipment Type                               No of Products          Therapy Area                                                No of Products
     Interventional Cardiology                        12                  Coronary artery disease                                        6
     Peripheral Vascular Devices                                 4        Atherosclerosis                                                3
     Cardiovascular Prosthetic Devices                           1        Carotid artery disease                                         1
     Source: Primary / Secondary Research                                 Coronary arteriosclerosis                                      1
     GlobalData
                                                                          Coronary artery lesions                                        1
                                                                          Coronary artery stenosis                                       1
                                                                          Iliac artery disease                                           1
                                                                          Source: Primary / Secondary Research
                                                                          GlobalData


     Abbott Vascular Inc. Key Pipeline Products by Equipment Type




      Source: Primary / Secondary Research
      GlobalData




     Abbott Vascular Inc. Key Pipeline Products by                        Abbott Vascular Inc. Key Pipeline Products by Trial Phase
     Development Stage
     Developmental Stage                         No of Products           Trial Phase                                                 No of Products
     Clinicals                                   12                       Phase IV                                                2
     Pre-Clinicals                                          2             Phase III                                               8
     Early development                                      2             Phase II                                                1
     No Specific Phase                                      1             Phase I                                                 2
     Source: Primary / Secondary Research                                 Source: Primary / Secondary Research
     GlobalData                                                           GlobalData




Abbott Vascular Inc. - Product Pipeline Analysis                                                                                Reference Code: GDME6037PD

Source : www.globalcompanyintelligence.com                                                                                                               Page 1
     Table of Contents
     Table of Contents................................................................................................................................................................................................................................................................... 2
     List of Tables .......................................................................................................................................................................................................................................................................... 4
     List of Figures......................................................................................................................................................................................................................................................................... 6
     Key Facts ............................................................................................................................................................................................................................................................................... 7
     Abbott Vascular Inc. - Major Products and Services.............................................................................................................................................................................................................. 8
           Abbott Vascular Inc. Pipeline Products by Equipment Type ......................................................................................................................................................................................... 10
           Abbott Vascular Inc. Pipeline Products by Development Stage .................................................................................................................................................................................... 12
           Abbott Vascular Inc. Pipeline Products by Therapy Area .............................................................................................................................................................................................. 14
           Abbott Vascular Inc. Pipeline Products by Trial Phase ................................................................................................................................................................................................. 16
           Abbott Vascular Inc. Pipeline Products by Milestone Summary .................................................................................................................................................................................... 18
           Absolute Pro Peripheral Self-Expanding Stent System ................................................................................................................................................................................................. 20
                 Product Status......................................................................................................................................................................................................................................................... 20
                 Product Description ................................................................................................................................................................................................................................................. 20
                 Product Milestone ................................................................................................................................................................................................................................................... 20
                 Absolute Pro Peripheral Self-Expanding Stent System Clinical Trial...................................................................................................................................................................... 21
                 Product Patent Details ............................................................................................................................................................................................................................................ 23
           AVJ-09-385.................................................................................................................................................................................................................................................................... 23
                 Product Status......................................................................................................................................................................................................................................................... 23
                 Product Description ................................................................................................................................................................................................................................................. 23
                 AVJ-09-385 Clinical Trial......................................................................................................................................................................................................................................... 24
           Bioabsorbable Everolimus Eluting Coronary Stent........................................................................................................................................................................................................ 27
                 Product Status......................................................................................................................................................................................................................................................... 27
                 Product Description ................................................................................................................................................................................................................................................. 27
                 Product Milestone ................................................................................................................................................................................................................................................... 27
                 Bioabsorbable Everolimus Eluting Coronary Stent Clinical Trial............................................................................................................................................................................. 28
                 Product Patent Details ............................................................................................................................................................................................................................................ 30
           Bioresorbable Vascular Scaffold.................................................................................................................................................................................................................................... 31
                 Product Status......................................................................................................................................................................................................................................................... 31
                 Product Description ................................................................................................................................................................................................................................................. 31
                 Product Milestone ................................................................................................................................................................................................................................................... 31
                 Bioresorbable Vascular Scaffold Clinical Trial ........................................................................................................................................................................................................ 32
           Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 ................................................................................................................................................................ 34
                 Product Status......................................................................................................................................................................................................................................................... 34
                 Product Description ................................................................................................................................................................................................................................................. 34
                 Emboshield Pro Rapid Exchange Embolic Protection System Generation 5 Clinical Trial ..................................................................................................................................... 34
                 Product Patent Details ............................................................................................................................................................................................................................................ 37
           Herculink Elite Renal Stent System ............................................................................................................................................................................................................................... 37
                 Product Status......................................................................................................................................................................................................................................................... 37
                 Product Description ................................................................................................................................................................................................................................................. 38
                 Product Milestone ................................................................................................................................................................................................................................................... 38
                 Herculink Elite Renal Stent System Clinical Trial.................................................................................................................................................................................................... 38
           MitraClip Device............................................................................................................................................................................................................................................................. 39
                 Product Status......................................................................................................................................................................................................................................................... 39
                 Product Description ................................................................................................................................................................................................................................................. 39
                 Product Milestone ................................................................................................................................................................................................................................................... 39
                 MitraClip Device Clinical Trial ................................................................................................................................................................................................................................. 40
                 Product Patent Details ............................................................................................................................................................................................................................................ 44
           NC TREK Coronary Dilatation Catheter ........................................................................................................................................................................................................................ 47
                 Product Status......................................................................................................................................................................................................................................................... 47
                 Product Description ................................................................................................................................................................................................................................................. 47
           Next-Generation Frontline Balloon Dilatation Catheter ................................................................................................................................................................................................. 47
                 Product Status......................................................................................................................................................................................................................................................... 47
                 Product Description ................................................................................................................................................................................................................................................. 47
                 Product Patent Details ............................................................................................................................................................................................................................................ 47
           Next-Generation Xience V Drug-Eluting Stent............................................................................................................................................................................................................... 48
                 Product Status......................................................................................................................................................................................................................................................... 48
                 Product Description ................................................................................................................................................................................................................................................. 48
           Omnilink Elite................................................................................................................................................................................................................................................................. 48
                 Product Status......................................................................................................................................................................................................................................................... 48
                 Product Description ................................................................................................................................................................................................................................................. 48

Abbott Vascular Inc. - Product Pipeline Analysis                                                                                                                                                                                                       Reference Code: GDME6037PD

Source : www.globalcompanyintelligence.com                                                                                                                                                                                                                                                     Page 2
                 Omnilink Elite Clinical Trial...................................................................................................................................................................................................................................... 48
           Side Branch Access Everolimus Eluting Coronary Stent System ................................................................................................................................................................................. 51
                 Product Status......................................................................................................................................................................................................................................................... 51
                 Product Description ................................................................................................................................................................................................................................................. 51
                 Product Patent Details ............................................................................................................................................................................................................................................ 51
           Thinman DES ................................................................................................................................................................................................................................................................ 52
                 Product Status......................................................................................................................................................................................................................................................... 52
                 Product Description ................................................................................................................................................................................................................................................. 52
           TREK Coronary Dilatation Catheter............................................................................................................................................................................................................................... 52
                 Product Status......................................................................................................................................................................................................................................................... 52
                 Product Description ................................................................................................................................................................................................................................................. 52
                 Product Milestone ................................................................................................................................................................................................................................................... 52
                 TREK Coronary Dilatation Catheter Clinical Trial ................................................................................................................................................................................................... 53
           XIENCE NANO .............................................................................................................................................................................................................................................................. 55
                 Product Status......................................................................................................................................................................................................................................................... 55
                 Product Description ................................................................................................................................................................................................................................................. 55
                 Product Milestone ................................................................................................................................................................................................................................................... 56
                 XIENCE NANO Clinical Trial................................................................................................................................................................................................................................... 56
                 Product Patent Details ............................................................................................................................................................................................................................................ 58
           XIENCE PRIME Everolimus Eluting Coronary Stent System ........................................................................................................................................................................................ 59
                 Product Status......................................................................................................................................................................................................................................................... 59
                 Product Description ................................................................................................................................................................................................................................................. 59
                 Product Milestone ................................................................................................................................................................................................................................................... 59
                 XIENCE PRIME Everolimus Eluting Coronary Stent System Clinical Trial............................................................................................................................................................. 60
                 Product Patent Details ............................................................................................................................................................................................................................................ 66
           ZoMaxx Drug-Eluting Coronary Stent System............................................................................................................................................................................................................... 66
                 Product Status......................................................................................................................................................................................................................................................... 66
                 Product Description ................................................................................................................................................................................................................................................. 67
     Abbott Vascular Inc. - Key Competitors ............................................................................................................................................................................................................................... 68
     Abbott Vascular Inc. - Key Employees................................................................................................................................................................................................................................. 69
     Abbott Vascular Inc. - Locations And Subsidiaries .............................................................................................................................................................................................................. 70
           Head Office.................................................................................................................................................................................................................................................................... 70
           Other Locations & Subsidiaries ..................................................................................................................................................................................................................................... 70
     Recent Developments.......................................................................................................................................................................................................................................................... 71
                 Sep 16, 2010: Abbott Vascular To Present Data On XIENCE V And Vascular Pipeline At TCT 2010 ................................................................................................................... 71
                 Jun 11, 2010: Abbott Lays Off 120 Jobs In Temecula, French Valley And Santa Clara, California........................................................................................................................ 71
                 May 25, 2010: HCRI Expands DAPT Study Into Europe ........................................................................................................................................................................................ 71
                 Feb 26, 2010: NIH Clinical Trial Comparing Two Stroke Prevention Procedures Shows Surgery And Stenting Equally Safe And Effective ........................................................ 72
                 Sep 24, 2009: Results From Abbott's PROSPECT Study Provide New Insight Into Role Of Vulnerable Plaque In Coronary Artery Disease ...................................................... 73
     Appendix .............................................................................................................................................................................................................................................................................. 75
           Methodology .................................................................................................................................................................................................................................................................. 75
           About GlobalData .......................................................................................................................................................................................................................................................... 75
           Contact Us ..................................................................................................................................................................................................................................................................... 75
           Disclaimer ...................................................................................................................................................................................................................................................................... 75




Abbott Vascular Inc. - Product Pipeline Analysis                                                                                                                                                                                                      Reference Code: GDME6037PD

Source : www.globalcompanyintelligence.com                                                                                                                                                                                                                                                    Page 3
     List of Tables
     Abbott Vascular Inc., Key Facts ............................................................................................................................................................................................................................................ 1

     Abbott Vascular Inc. Key Pipeline Products by Equipment Type .......................................................................................................................................................................................... 1

     Abbott Vascular Inc. Key Pipeline Products by Therapy Area .............................................................................................................................................................................................. 1

     Abbott Vascular Inc. Key Pipeline Products by Developm
								
To top